Roche lung cancer treatment reports promising results in Phase III
pharmafile | March 22, 2021 | News story | Sales and Marketing | Roche, oncology
Roche’s IMpower010 study, evaluating Tecentriq (atezolizumab) compared with best supportive care, has shown significant improvement in disease-free survival (DFS) in the treatment of early stage, non-small cell lung cancer (NSCLC), it was announced today.
The Phase III study has become the first to show that a cancer immunotherapy improves DFS in people with resectable early stage lung cancer compared with best supportive care, with Tecentriq used as adjuvant therapy following surgery and chemotherapy.
Levi Garraway, Roche’s Chief Medical Officer and Head of Global Product Development, said: “With these landmark results, Tecentriq has become the first cancer immunotherapy to help many people with resectable early lung cancer live longer without their cancer returning.
“We’re excited by the clinical benefit adjuvant Tecentriq may bring to lung cancer patients, particularly in the PD-L1-positive population. We will submit these data to regulatory authorities as soon as possible.”
Follow-up will continue with planned analysis of DFS in the overall intent-to-treat population, which at the time of analysis did not cross the threshold, and overall survival data, which were immature at the time of interim analysis.
Roche will present results from the Impower010 study at an upcoming medical meeting and it will subsequently be submitted to global health authorities, including the FDA and EMA.
Tecentriq has previously shown benefits in various types of lung cancer, with five currently approved indications in markets around the world. It was also the first approved cancer immunotherapy for front-line treatment of adults with extensive-stage small cell lung cancer (SCLC) in combination with carboplatin and etoposide.
Roche has an extensive development programme for Tecentriq, including multiple ongoing and planned Phase III studies across different lung, genitourinary, skin, breast, gastrointestinal, gynaecological, and head and neck cancers. This includes studies evaluating Tecentriq both alone and in combination with other medicines, as well as studies in metastatic, adjuvant, and neoadjuvant settings across various tumour types.
Kat Jenkins
Related Content
Roche’s Alecensa approved by FDA as lung cancer treatment
Roche has announced that the US Food and Drug Administration (FDA) has approved Alecensa (alectinib) …
Genentech’s Columbi meets primary endpoint in phase 3 trial for lymphoma treatment
Genentech, part of the Roche Group, has announced that its phase 3 STARGLO trial has …
Curve Therapeutics’ CSO publishes research on HIF inhibition for cancer treatment
Curve Therapeutics has announced that its chief scientific officer, Professor Ali Tavassoli has published research …
